Health Research Council, New Zealand   Report issue

Academic/Hospital Phase 3 Phase 4
Founded: Auckland New Zealand (1990)

Organization Overview

First Clinical Trial
2003
NCT00193856
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Health Research Council, New Zealand

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blood Coagulation Disorders (Phase 3)

Brain Injuries (Phase 3)

Brain Injuries, Traumatic (Phase 3)

Delayed Graft Function (Phase 3)

Hemostatic Disorders (Phase 3)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 3)

Leg Ulcer (Phase 3)

Multiple Trauma (Phase 3)

Prostatic Neoplasms (Phase 3)

Ulcer (Phase 3)

Varicose Ulcer (Phase 3)

Wounds and Injuries (Phase 3)

Wounds, Nonpenetrating (Phase 3)

Wounds, Penetrating (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 7